ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for cancer. Headquartered in Pennsylvania, the company aims to address unmet medical needs in oncology by advancing targeted treatments for non-small cell lung cancer (NSCLC) and other solid tumors. The company's lead product candidate is firmonertinib, an oral, brain-penetrant, mutation-selective epidermal growth factor receptor (EGFR) inhibitor currently in Phase 3 clinical trials. ArriVent's pipeline also includes antibody-drug conjugates (ADCs), such as ARR-217 for gastrointestinal cancers, and other early-stage solid tumor candidates. The company operates by identifying and in-licensing promising oncology assets from global partners to accelerate their clinical development and commercialization.
